Time-kill studies with micafungin and voriconazole against Candida glabrata intracellularly in human monocyte-derived macrophages and extracellularly in broth

Diagnostic Microbiology and Infectious Disease

Volumn 70, Issue 4, 2011, Pages 468-474

  Baltch, Aldona L ^a,b   Ritz, William ^a,b   Bopp, Lawrence H ^a,c   Michelsen, Phyllis B ^a,b   Smith, Raymond P ^a,b  

^a STRATTON VA MEDICAL CENTER   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

^c Center for Agriculture and Natural Resources   (United States)

Author keywords

Antifungal combinations; Candida glabrata; Micafungin; Time kill methodology; Voriconazole

Indexed keywords

FLUCONAZOLE; MICAFUNGIN; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA GLABRATA; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; FETAL CALF SERUM; FUNGAL STRAIN; FUNGUS ISOLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MACROPHAGE; MINIMUM INHIBITORY CONCENTRATION; MONOCYTE; NONHUMAN; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; CANDIDA GLABRATA; DRUG SYNERGISM; ECHINOCANDINS; HUMANS; LIPOPEPTIDES; MACROPHAGES; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; PYRIMIDINES; TIME FACTORS; TRIAZOLES;

EID: 79960361012     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2011.04.008     Document Type: Article

References (30)

1. Andes D.R., Diekema D.J., Pfaller M.A., Marchillo K., Bohrmueller J. In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C glabrata in a neutropenic murine candidiasis model. Antimicrob. Agents Chemother. 2008, 52:3497-3503.
2. Baltch A.L., Bopp L.H., Smith R.P., Ritz W.J., Carlyn C.J., Michelsen P.B. Effects of voriconazole, granulocyte-macrophages colony-stimulating factor and interferon gamma on intracellular fluconazole-resistant Candida glabrata and C krusei in human monocyte-derived macrophages. Diagn. Microbiol. Infect. Dis. 2005, 52:299-304.
3. Baltch A.L., Bopp L.H., Smith R.P., Ritz W.J., Michelsen P.B. Anticandidal effects of voriconazole and caspofungin, singly and in combination, against Candida glabrata, extracellularly and intracellularly in granulocyte-macrophages colony-stimulating factor activated human monocytes. J. Antimicrob. Chemother. 2008, 62:1285-1290.
4. Baltch A.L., Lawrence D., Ritz W.J., Andersen N., Bopp L.H., Michelsen P.B., Smith R.P. 2009.
5. Bopp L.H., Baltch A.L., Ritz W.J., Michelsen P.B., Smith R.P. Antifungal effect of voriconazole on intracellular Candida glabrata, Candida krusei and Candida parapsilosis in human monocyte-derived macrophages. J. Med. Microbiol. 2006, 55:865-870.
6. Bopp L.H., Baltch A.L., Ritz W.J., Smith R.P. 2009.
7. Cappelletty D., Eiselstein-Mc Kitrick K. The echinocandins. Pharmacotherapy 2007, 27:369-388.
8. Clancy C.J., Huang H., Cheng S., Derendorf H., Nguyen M.H. Characterizing the effects of caspofungin on Candida albicans, Candida parapsilosis and Candida glabrata isolates by simultaneous time-kill and post antifungal-effect experiments. Antimicrob. Agents Chemother. 2006, 50:2569-2572.
9. Ernst E.J., Roling E.E., Petzold C.R., Keele D.J., Klepser M.E. In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill and post antifungal-effect studies. Antimicrob. Agents Chemother. 2002, 50:2569-2572.
10. Frank U., Greiner M., Engels I., Daschner F.D. Effects of caspofungin (MK-0991) and anidulafungin (LY 303366) on phagocytosis, oxidative burst and killing of Candida albicans by human phagocytes. Eur. J. Clin. Microbiol. Infect. Dis. 2004, 23:729-731.
11. Hoffman H.L., Ernst E.J., Klepser M.E. Novel triazole antifungal agents. Expert. Opin. Invest. Drugs 2000, 9:593-605.
12. Horn D.L., Neofytos D., Anaissie E.J., Fishman J.A., Steinbach W.J., Olyaei A.J., Marr K.A., Pfaller M.A., Chang C.H., Webster K.M. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin. Infect. Dis. 2009, 48:1695-1703.
13. Klepser M.E., Ernst E.J., Lewis R.E., Ernst M.E., Pfaller M.A. Influence of test conditions on antifungal time-kill curve results: proposal for standardized methods. Antimicrob. Agents Chemother. 1998, 42:1207-1212.
14. Klepser M.E., Malone D., Lewis R.E., Ernst E.J., Pfaller M.A. Evaluation of voriconazole pharmacodynamics using time-kill methodology. Antimicrob. Agents Chemother. 2000, 44:1917-1920.
15. Malani A., Hmoud J., Chiu L., Carver P.L., Bielaczyc A., Kauffman C.A. Candida glabrata fungemia: experience in a tertiary care center. Clin. Infect. Dis. 2005, 41:975-981.
16. Maródi L., Korchek H.M., Johnston R.B. Mechanisms of host defense against Candida species: I. Phagocytosis by monocytes and monocyte-derived macrophages. J. Immunol. 1991, 146:2783-2789.
17. Maródi L., Forehand J.R., Johnston R.B. Mechanisms of host defense against Candida species: II. Biochemical basis for the killing of Candida by mononuclear phagocytes. J. Immunol. 1991, 146:2790-2794.
18. Odabasi Z., Paetznick V., Rex J.H., Ostrosky-Zeichner L. Effects of serum on in vitro susceptibility testing of echinocandins. Antimicrob. Agents Chemother. 2007, 51:4214-4216.
19. Paderu P., Garcia-Effron G., Balashov S., Delmas G., Park S., Perlin D.S. Serum differentially alters antifungal properties of echinocandin drugs. Antimicrob. Agents Chemother. 2007, 51:2253-2256.
20. Pappas P.G., Kauffman C.A., Andes D., Benjamin D.K., Calandra T.F., Edwards J.E., Filler S.G., Fisher J.F., Kulberg B.J., Ostrosky-Zeichner L., Reboli A.C., Rex J.H., Walsh T.J., Sobel J.D. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Disease Society of America. Clin. Infect. Dis. 2009, 48:503-535. Infectious Disease Society of America.
21. Pfaller M.A., Castanheira M., Messer S.A., Moet G.J., Jones R.N. Variation in Candida spp distribution and antifungal resistance rates among blood stream infection isolates by patient age: report from the SENTRY Antimicrobial Surveillance Program (2008-2009). Diagn. Microbiol. Infect. Dis. 2010, 68:278-283.
22. Pfaller M.A., Castanheira M., Messer S.A., Moet G.J., Jones R.N. Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the Sentry Antimicrobial Surveillance Program 2009. Diagn. Microbiol. Infect. Dis. 2011, 69:45-50.
23. Pfaller M.A., Moet G.J., Messer S.A., Jones R.N., Castanheira M. Geographic variation in species distribution and echinocandin and azole antifungal resistance rates among Candida blood-stream infection isolates: report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009). J. Clin. Microbiol. 2011, 49:396-399.
24. Pound M.W., Towsend M.L., Drew R.H. Echinocandin pharmocodynamics: review and clinical implications. J. Antimicrob. Chemother. 2010, 65:1108-1118.
25. Smith RP, Baltch AL, Ritz W, Bopp LH (2009) Comparison of time-kill curves and post-antifungal effects (PAFE) of anidulafungin, caspofungin and micafungin against fluconazole-resistant Candida glabrata and Candida parapsilosis. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstract 1 A581, page 19, San Francisco, CA.
26. Stuart A., Ord J.K. Kendall's advanced theory of statistics 1991, Vol 2:1139. Oxford University Press, New York, NY, Section 29.38.
27. Stuart A., Ord J.K. Kendall's advanced theory of statistics 1991, Vol 2:1149. Oxford University Press, New York, NY, Section 29.58.
28. Vitale R.G., Afeltra J., Dannaoui E. Antifungal combinations. Methods Mol. Med. 2005, 118:143-152.
29. Wiederhold N.P., Najvar L.K., Bocanegra R., Molina D., Olivo M., Graybill J.R. In vitro efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera. Antimicrob. Agents Chemother. 2007, 51:1616-1620.
30. Wisplinghoff H., Bischoff T., Tallent S.M., Seifert H., Wenzel R.P., Edmond M.B. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 2004, 39:309-317.